Target intelligence / Profile preview

Nuclear factor of activated T-cells, cytoplasmic 2 (NFATC2)

Target
NFATC2
Molecular classification
Transcription factor, DNA-binding protein, REL family protein
01

Overview

Nuclear factor of activated T-cells, cytoplasmic 2 (NFATC2) is a member of the NFAT transcription factor family, crucial for T-cell development and immune function. It is a DNA-binding protein that resides in the cytoplasm and translocates to the nucleus upon T-cell receptor activation, where it regulates expression of key cytokines fundamental to immune response. NFATC2 interacts with multiple cofactors and is involved in various signaling pathways, including those influencing cell migration and chondrogenesis. Genetic alterations of NFATC2, such as oncogenic fusion with EWSR1, have been implicated in certain cancers. Pharmacologically, NFATC2 is targeted indirectly by calcineurin inhibitors (cyclosporine, tacrolimus) used in transplantation and autoimmune settings, which block its activation and nuclear translocation.

Other names
NFAT1NFATpNF-ATc2NFAT pre-existing subunitNFAT transcription complex, nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2NF-ATPnuclear factor of activated T-cells, preexisting component
02

Mechanism of action

Inhibition of calcineurin prevents NFATC2 dephosphorylation and nuclear translocation, blocking cytokine gene transcription (mechanism for cyclosporine and tacrolimus)

03

Biological functions

Inducible expression of cytokine genes in T-cells (e.g., IL-2, IL-3, IL-4, TNF-alpha, GM-CSF)Regulation of immune responseTranscriptional regulation following T-cell receptor stimulationNegative regulation of chondrogenesisPromotion of invasive cell migration via WNT5A signalingControl of mast cell accessory function bridging innate and adaptive immunity
04

Disease associations

Cancer (bone sarcoma, B-cell lymphoma, lung adenocarcinoma)Joint contractures and osteochondromasInflammationPossible role in bone tumors with EWSR1-NFATC2 fusion
05

Safety considerations

Immune suppression, increased risk of infections (associated with indirect inhibition via calcineurin inhibitors)Therapeutic challenges due to broad role in immune regulationPotential oncogenic fusion events (EWSR1-NFATC2)
06

Interacting drugs

Cyclosporine

2 more in the full profile.

07

Biomarkers

Expression of NFATC2 protein in T cells as a pharmacodynamic marker for calcineurin inhibitor activityEWSR1-NFATC2 fusion for bone tumor diagnostics

Beyond the preview

Go deeper on Nuclear factor of activated T-cells, cytoplasmic 2 (NFATC2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuclear factor of activated T-cells, cytoplasmic 2 (NFATC2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call